ArriVent BioPharma (NASDAQ:AVBP) Trading Up 10.5% – Here’s What Happened

ArriVent BioPharma, Inc. (NASDAQ:AVBP) shares were up 10.5% on Friday . The company traded as high as $30.04 and last traded at $29.8150. Approximately 126,190 shares traded hands during mid-day trading, a decline of 74% from the average daily volume of 476,343 shares. The stock had previously closed at $26.97.

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on AVBP shares. Truist Financial upgraded shares of ArriVent BioPharma to a “strong-buy” rating in a report on Monday, May 4th. Weiss Ratings restated a “sell (d-)” rating on shares of ArriVent BioPharma in a report on Monday, April 20th. Citigroup lowered their price target on shares of ArriVent BioPharma from $45.00 to $43.00 and set a “buy” rating on the stock in a report on Wednesday, May 13th. Oppenheimer restated an “outperform” rating and set a $50.00 price target (up from $44.00) on shares of ArriVent BioPharma in a report on Friday, March 6th. Finally, HC Wainwright boosted their price target on shares of ArriVent BioPharma from $42.00 to $44.00 and gave the company a “buy” rating in a report on Friday, March 6th. Two analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, ArriVent BioPharma presently has an average rating of “Moderate Buy” and a consensus target price of $43.13.

ArriVent BioPharma Trading Up 12.5%

The firm has a market cap of $1.41 billion, a P/E ratio of -8.70 and a beta of 1.51. The business’s fifty day moving average price is $26.95 and its two-hundred day moving average price is $23.96.

ArriVent BioPharma (NASDAQ:AVBP) last released its quarterly earnings results on Monday, May 11th. The company reported ($0.96) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.88) by ($0.08). Research analysts predict that ArriVent BioPharma, Inc. will post -3.78 EPS for the current fiscal year.

Hedge Funds Weigh In On ArriVent BioPharma

Several large investors have recently made changes to their positions in the business. Infinitum Asset Management LLC lifted its position in shares of ArriVent BioPharma by 6.6% during the 4th quarter. Infinitum Asset Management LLC now owns 4,123,923 shares of the company’s stock worth $82,973,000 after purchasing an additional 255,000 shares during the last quarter. Suvretta Capital Management LLC increased its position in ArriVent BioPharma by 10.9% during the fourth quarter. Suvretta Capital Management LLC now owns 4,106,035 shares of the company’s stock worth $82,613,000 after acquiring an additional 402,583 shares during the period. Vanguard Group Inc. increased its position in ArriVent BioPharma by 36.8% during the third quarter. Vanguard Group Inc. now owns 2,029,531 shares of the company’s stock worth $37,445,000 after acquiring an additional 545,991 shares during the period. State Street Corp increased its position in ArriVent BioPharma by 6.3% during the fourth quarter. State Street Corp now owns 1,091,980 shares of the company’s stock worth $21,971,000 after acquiring an additional 64,352 shares during the period. Finally, Vivo Capital LLC bought a new position in ArriVent BioPharma during the first quarter worth $20,438,000. Institutional investors and hedge funds own 9.48% of the company’s stock.

ArriVent BioPharma Company Profile

ArriVent BioPharma, Inc operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers in the United States. It also engages in the development and commercialization of targeted cancer therapies for non-small cell lung cancer (NSCLC) and other solid tumors. In addition, the company develops Furmonertinib, a third-generation tyrosine kinase inhibitor that is in multiple clinical trials across a range of epidermal growth factor receptor mutations (EFGRm) in non-small cell lung cancer (NSCLC), including a phase 3 clinical trial for treatment of patients with metastatic EFGRm NSCLC; phase 1b clinical trial for treatment of patients with NSCLC with other EGFR mutations and NSCLC with HER2 Exon 20 insertion mutations; and ARR-002.